{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
mmae
to a specific field?
Status:
Investigational
Source:
INN:indusatumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:iladatuzumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:telisotuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sofituzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:losatuxizumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lifastuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pinatuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:azintuxizumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:glembatumumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02837991: Phase 1 Interventional Terminated Renal Cell Carcinoma (RCC)
(2016)
Source URL:
Class:
CONCEPT
